3 pharmaceutical companies have approved injection drugs or have a positive impact on performance

According to incomplete industry statistics, as of March 4, a total of 647 injectable drugs (1018 acceptance numbers) have applied /as the application for consistency evaluation, of which 625 additional applications, according to the new 4 categories of reported production of 393In addition, to date, 30 injections (36 acceptance numbers) from 25 companies have passed the consistency evaluation first, and in the three months to 2020 alone, the company's injection products have passed the consistency evaluation
According to the relevant regulations, these varieties will receive appropriate support in the payment of medical insurance, medical institutions should be preferred procurement and clinical priority selection, conducive to expanding the market sales of the relevant company products, or have a positive impact on the company's operating performance
Red Day Pharmaceuticals sodium hydrochloric acid moxisax aptly approved on the evening of March 3, Red Day Pharmaceuticals issued a notice that the company's sodium hydrochloric acid moxisaxachlor sodium chloride injection was approved, this is the first of the same varieties in china in accordance with the new registered classification - chemicals 4 categories declared and approved varieties, its quality, efficacy and original research drugs, such as the same through the consistent evaluation
According to Minet, Moxisha star was developed by Bayer and was approved to enter the Chinese market in 2002, with the product named "Bay Forle"Moxisastar has two tablets and injections, of which 80% are injectable, including the hydrochloric acid moxisastar injection and the sodium chloride injection of moxisastar hydrochloric acid
Data show that in 2018, the sales of Moxixa injections in China's public medical institutions terminal selling more than 3 billion yuan, an increase of 27.20% year-on-yearByule's market share declined as domestic companies' products were approved, but Bayer's third-quarter 2019 report noted a 32.8 percent increase in sales, mainly due to higher sales in China
Xinhua Pharmaceutical Ida Lafeng Injection Approved Xinhua Pharmaceuticals announced on the evening of March 3, the company recently received the Approval of the State Drug Administration to issue the Ida Laafeng injection "drug registration approval."
Data show that Ida laFeng is a brain protector (free radical scavenger), in 2004 in China was approved for listing, has been written into the domestic relevant drug guidelines, the category of health insurance is Class B
According to minet data, sales of China's public medical institutions terminal Inada in 2018 exceeded 5 billion yuan, and 22 domestic enterprises (including Xinhua Pharmaceuticals) have received production approval
China Resources Pharmaceuticals subsidiary of the fentanyol curry morphine due to injection sumolys was approved China Resources Pharmaceuticals recently also announced that the company's China Resources Shuanghe wholly owned subsidiary Shuanghe Limin received fentanyora curry because of injections used to treat premature newborn primary apneaAs of the announcement date, Shuanghe Limin has invested about RMB 5.12 million in research and development of the drug
It is reported that the current domestic import of fentanyoric morphine because of the injection of injections for the Italian Casey pharmaceutical production, the commodity name "DoubleUno." Data show that in 2018, the international market sales of fentanyoric morphine due to injections were $33.5 millionThere are currently three listed imitation pharmaceutical manufacturers, respectively, Chengdu Yuandong Biopharmaceutical Co., Ltd., Shanxi Guorun Pharmaceutical Co., Ltd., Guorui Pharmaceutical Co., Ltd., The National Pharmaceutical Group
In addition, according to IMS statistics, the national sales of pyrirador-based morphine injections in the fourth quarter of 2018 to the third quarter of 2019 were 260 million yuan, the enterprise share pattern ranked 71% of Cathy Pharmaceuticals, Chengdu Yuandong Biopharmaceutical Co., Ltd 28%, Shanxi Guorun Pharmaceutical Co., Ltd 0.4%, And Guorui Pharmaceutical Co., Ltd 0.2%.